Atea Pharmaceuticals, Inc.

Ownership Transactions Reported by 12 Insiders

Symbol
AVIR on Nasdaq
Location
225 Franklin Street, Suite 2100, Boston, MA

Insiders trading volume in the past year

Atea Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Jean-Pierre Sommadossi President, CEO, and Chairman, Director $19.2M -$238K -1.23% Jan 31, 2025
Andrea Corcoran Chief Financial Officer, Executive Vice President, Legal and Secretary $2.23M Jan 31, 2025
Franklin M. Berger Director $1.71M -$942K -35.6% Jan 15, 2025
John Vavricka Chief Commercial Officer $439K Jan 31, 2025
Bruno Lucidi Director $436K Jun 21, 2024
Bruce Polsky Director $347K -$61.1K -15% Jun 20, 2024
Polly A. Murphy Director $344K Jun 21, 2024
Janet Hammond Chief Development Officer $283K Jan 31, 2025
Barbara Gayle Duncan Director $236K Jun 21, 2024
Jerome M. Adams Director $236K Jun 21, 2024
Maria Arantxa Horga Chief Medical Officer $216K Jan 31, 2025
Wayne Foster EVP, Chief Accounting Officer $180K Jan 31, 2025

Recent Insider Transactions by Companies or Individuals for Atea Pharmaceuticals, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.